|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rubin KM and Lawrence D: Your patient with
melanoma: Staging, prognosis, and treatment. Oncology (Williston
Park). 23 8 Suppl:S13–S21. 2009.
|
|
3
|
Chan JK: Virus-associated neoplasms of the
nasopharynx and sinonasal tract: Diagnostic problems. Mod Pathol.
30(s1): S68–S83. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grossman D and Altieri DC: Drug resistance
in melanoma: Mechanisms, apoptosis, and new potential therapeutic
targets. Cancer Metastasis Rev. 20:3–11. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gogas HJ, Kirkwood JM and Sondak VK:
Chemotherapy for metastatic melanoma: Time for a change. Cancer.
109:455–464. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mandarà M, Nortilli R, Sava T and Cetto
GL: Chemotherapy for metastatic melanoma. Expert Rev Anticancer
Ther. 6:121–130. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cummins DL, Cummins JM, Pantle H,
Silverman MA, Leonard AL and Chanmugam A: Cutaneous malignant
melanoma. Mayo Clin Proc. 81:500–507. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lens MB and Dawes M: Interferon alfa
therapy for malignant melanoma: A systematic review of randomized
controlled trials. J Clin Oncol. 20:1818–1825. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sabel MS and Sondak VK: Pros and cons of
adjuvant interferon in the treatment of melanoma. Oncologist.
8:451–458. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McLoughlin JM, Zager JS, Sondak VK and
Berk LB: Treatment options for limited or symptomatic metastatic
melanoma. Cancer Control. 15:239–247. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Garbe C, Eigentler TK, Keilholz U,
Hauschild A and Kirkwood JM: Systematic review of medical treatment
in melanoma: current status and future prospects. Oncologist.
16:5–24. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lesinski GB, Anghelina M, Zimmerer J,
Bakalakos T, Badgwell B, Parihar R, Hu Y, Becknell B, Abood G,
Chaudhury AR, et al: The antitumor effects of IFN-alpha are
abrogated in a STAT1-deficient mouse. J Clin Invest. 112:170–180.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lesinski GB, Trefry J, Brasdovich M,
Kondadasula SV, Sackey K, Zimmerer JM, Chaudhury AR, Yu L, Zhang X,
Crespin TR, et al: Melanoma cells exhibit variable signal
transducer and activator of transcription 1 phosphorylation and a
reduced response to IFN-alpha compared with immune effector cells.
Clin Cancer Res. 13:5010–5019. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bearzatto A, Orlandi L, De Marco C,
Daidone MG and Zaffaroni N: Lack of p21waf1 and p27kip1 protein
induction by interferon-alpha2a in human melanoma cell lines.
Melanoma Res. 9:457–463. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou Y, Wang S, Yue BG, Gobl A and Oberg
K: Effects of interferon alpha on the expression of p21cip1/waf1
and cell cycle distribution in carcinoid tumors. Cancer Invest.
20:348–356. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hahne M, Rimoldi D, Schröter M, Romero P,
Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard
D, et al: Melanoma cell expression of Fas(Apo-1/CD95) ligand:
Implications for tumor immune escape. Science. 274:1363–1366. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bullani R, Wehrli P, Viard-Leveugle I,
Rimoldi D, Cerottini JC, Saurat JH, Tschopp J and French LE:
Frequent downregulation of Fas (CD95) expression and function in
melanoma. Melanoma Res. 12:263–270. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Helmbach H, Rossmann E, Kern MA and
Schadendorf D: Drug-resistance in human melanoma. Int J Cancer.
93:617–622. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ekmekcioglu S, Okcu MF, Colome-Grimmer M,
Owen-Schaub L, Buzaid AC and Grimm EA: Differential increase of Fas
ligand expression on metastatic and thin or thick primary melanoma
cells compared with interleukin-10. Melanoma Res. 9:261–272. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim S, Chin K, Gray JW and Bishop JM: A
screen for genes that suppress loss of contact inhibition:
Identification of ING4 as a candidate tumor suppressor gene in
human cancer. Proc Natl Acad Sci USA. 101:16251–16256. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shiseki M, Nagashima M, Pedeux RM,
Kitahama-Shiseki M, Miura K, Okamura S, Onogi H, Higashimoto Y,
Appella E, Yokota J and Harris CC: p29ING4 and p28ING5 bind to p53
and p300 and enhance p53 activity. Cancer Res. 63:2373–2378.
2003.PubMed/NCBI
|
|
22
|
Li J, Martinka M and Li G: Role of ING4 in
human melanoma cell migration, invasion and patient survival.
Carcinogenesis. 29:1373–1379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li X, Cai L, Liang M, Wang Y, Yang J and
Zhao Y: Ing4 induces cell growth inhibition in human lung
adenocarcinoma A549 cells by means of Wnt-1/beta-catenin signaling
pathway. Anat Rec (Hoboken). 291:593–600. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bu Q, Wang A, Hamzah H, Waldman A, Jiang
K, Dong Q, Li R, Kim J, Turner D and Chang Q: CREB signaling is
involved in Rett syndrome pathogenesis. J Neurosci. 37:3735–3716.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Escudier B, Lassau N, Angevin E, Soria JC,
Chami L, Lamuraglia M, Zafarana E, Landreau V, Schwartz B, Brendel
E, et al: Phase I trial of sorafenib in combination with IFN
alpha-2a in patients with unresectable and/or metastatic renal cell
carcinoma or malignant melanoma. Clin Cancer Res. 13:1801–1809.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Garkavtsev I, Kozin SV, Chernova O, Xu L,
Winkler F, Brown E, Barnett GH and Jain RK: The candidate tumour
suppressor protein ING4 regulates brain tumour growth and
angiogenesis. Nature. 428:328–332. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wlodkowic D, Telford W, Skommer J and
Darzynkiewicz Z: Apoptosis and beyond: Cytometry in studies of
programmed cell death. Methods Cell Biol. 103:55–98. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fulda S and Debatin K: Extrinsic versus
intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene.
25:4798–4811. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hohlbaum AM, Moe S and Marshak-Rothstein
A: Opposing effects of transmembrane and soluble Fas ligand
expression on inflammation and tumor cell survival. J Exp Med.
191:1209–1220. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nagata S and Golstein P: The Fas death
factor. Science. 267:1449–1456. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thyrell L, Erickson S, Zhivotovsky B,
Pokrovskaja K, Sangfelt O, Castro J, Einhorn S and Grandér D:
Mechanisms of interferon-alpha induced apoptosis in malignant
cells. Oncogene. 21:1251–1262. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kaur S, Sassano A, Dolniak B, Joshi S,
Majchrzakkita B, Baker DP, Hay N, Fish EN and Platanias LC: Role of
the Akt pathway in mRNA translation of interferon-stimulated genes.
Proc Natl Acad Sci USA. 105:4808–4813. 2008. View Article : Google Scholar : PubMed/NCBI
|
